To the Editor: In their recent case series, Lintzeris and colleagues state that the symptoms leading to hospital presentation were “associated” with naltrexone implants.1
The full article is accessible to AMA
members and paid subscribers.
Login to MJA or subscribe now.
- St Vincent’s Hospital, Melbourne, VIC.
Correspondence: martyn.lloydjones@svhm.org.au
- 1. Lintzeris N, Lee S, Scopelliti L, et al. Unplanned admissions to two Sydney public hospitals after naltrexone implants. Med J Aust 2008; 188: 441-444. <MJA full text>
- 2. Ling W, Wesson DR. Naltrexone treatment for addicted health-care professionals: a collaborative private practice experience. J Clin Psychiatry 1984; 45 (9 Pt 2): 46-48.
- 3. Lloyd-Jones DM. Naltrexone implants: a clinician’s view. Of Substance 2006; 4 (3): 22-23.
- 4. Comer SD, Sullivan MA, Yu E, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2006; 63: 210-218.
- 5. Gibson AE, Degenhardt LJ, Hall WD. Opioid overdose deaths can occur in patients with naltrexone implants. Med J Aust 2007; 186: 152-153. <MJA full text>
Online responses are no longer available. Please refer to our instructions for authors page for more information.